By Aaron Tallent
A retrospective analysis of breast cancer patients at The University of Kansas Health System found no significant difference in neutropenia-related events (NREs) when pegfilgrastim was administered on the same day an individual received chemotherapy versus the next day.
The researchers call for larger interventional studies to evaluate the use of same-day pegfilgrastim (J Hematol Oncol Pharm 2023;13[5]:241-245).
“In curative-intent regimens for breast cancer, we did